(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine、(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine、Terbinafine (USAN/INN)

+ [7]

靶点

SQLE

作用方式

抑制剂

作用机制

SQLE抑制剂(角鲨烯单加氧酶抑制剂)

治疗领域

感染皮肤和肌肉骨骼疾病肿瘤+ [1]

在研适应症

股癣肝细胞癌

非在研适应症

甲癣糠疹体癣+ [2]

原研机构

GSK Plc

在研机构

Karo Healthcare AB中山大学肿瘤防治中心

非在研机构

Novartis AG

Novartis Pharmaceuticals Canada, Inc.

GSK Plc

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1998-04-29),

糠疹体癣足癣+ [2]

最高研发阶段(中国)临床前

特殊审评-

登录后查看时间轴

结构/序列

分子式C21H25N

InChIKeyDOMXUEMWDBAQBQ-WEVVVXLNSA-N

CAS号91161-71-6

关联

项与特比萘芬相关的临床试验

CTRI/2024/01/061561

/ Not yet recruiting临床3期IIT

Randomised control trial to study the effectiveness of Tablet Fluconazole, Capsule Itraconazole and Tablet Terbinafine in Superficial Dermatophytosis - NIL

开始日期2024-01-25

申办/合作机构-

IRCT20210611051539N4

/ Recruiting临床3期IIT

Formulation design and evaluation of the effect of hyaluronic acid hydrogel loaded with terbinafine lipid nanostructures in the treatment of patients with onychomycosis

开始日期2023-11-06

申办/合作机构

Mazandaran University of Medical Sciences

CTRI/2023/06/054377

/ Not yet recruiting临床3期IIT

Comparative Clinical Study To Evaluate The Efficacy Of Dadru Gajendra Sinh Lepa And Terbinafine Ointment In Management Of Dadru Kushtha W.R.T Tinea Cruris . - NIL

开始日期2023-06-30

申办/合作机构-

100 项与特比萘芬相关的临床结果

登录后查看更多信息

100 项与特比萘芬相关的转化医学

登录后查看更多信息

100 项与特比萘芬相关的专利（医药）

登录后查看更多信息

3,940

项与特比萘芬相关的文献（医药）

2026-02-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

The first case of subcutaneous Fusariosis in an immunocompetent host in China: A case report

Article

作者: Yang, Lianjuan ; Chen, Jian ; Yu, Qian ; He, Wenjing ; Liu, Mei

Fusarium falciforme has emerged as a significant human pathogen, primarily causing invasive infections in immunocompromised individuals. Here, we report the first confirmed case of F. falciforme subcutaneous infection in an immunocompetent Chinese patient which remains rare. A 75-year-old female presented with a dark red plaque on the dorsum of her left hand. Diagnosis was confirmed through histopathology, tissue culture, and internal transcribed spacer sequencing. The patient received combined oral therapy with itraconazole and terbinafine for 2 years, with a favorable outcome. This report alerts clinicians to the possibility of F. falciforme infections in healthy individuals and emphasizes the early diagnosis and timely treatment.

2025-12-31·Emerging Microbes & Infections

Alert on imported fungal infection: the first report of tinea capitis due to Microsporum audouinii in China

Article

作者: Yuan, Liyan ; Shen, Weiqin ; Liu, Yinghui ; Xie, Zhenmou ; Xue, Yaohua ; Liu, Hongfang ; Chen, Yangxia ; Lin, Eryi ; Mo, Binchi

We report cases of Microsporum audouinii infections on the scalp of three individuals from an African family, originating from Mali and residing in Guangzhou. This is the first time that M. audouinii has been reported in China. The index case involved a 2-year-old boy who presented with scalp patches and scaling for more than 1 year. Dermatological examination revealed scattered dark brown patches with scales on the scalp without noticeable alopecia or pustules. Fungal microscopy revealed the presence of Ectothrix hyphae and abundant clusters of arthroconidia. On Sabouraud Dextrose Agar, pale yellow cottony colonies with radial growth appeared within 4 days. Small colonies grown on the 1% yeast extract medium exhibited pyriform and clavate microconidia, septate, thick-walled macroconidia, and comb-like hyphae. rDNA ITS Molecular identification, Matrix-assisted laser desorption ionization time-of-flight mass spectrometry and whole-genome sequencing all confirmed the presence of M. audouinii. The patient's father and second-eldest brother, both asymptomatic carriers, had positive fungal cultures for scalp dandruff, which were also identified as M. audouinii. After failing a 6-week course of oral itraconazole at 0.05 g/day with poor adherence, the patient was switched to intermittent oral terbinafine (0.08 g/day for 18 weeks) which resulted in minimal arthroconidia presence on the scalp and negative fungal culture. The father and second-eldest brother were each administered oral terbinafine at 0.25 and 0.125 g/day for 4 weeks, respectively, with negative fungal cultures post-treatment. Given the epidemiological characteristics of M. audouinii, vigilance is warranted for potential imported infections and risk of outbreaks in China.

2025-12-31·Emerging Microbes & Infections

Genomic epidemiology and antifungal resistance of emerging Trichophyton indotineae in China

Article

作者: Li, Xiaofang ; Liu, Weida ; Xie, Wenting ; Kong, Xue ; Tsui, Clement K. M. ; Liang, Guanzhao ; She, Xiaodong

The emergence and spread of antifungal-resistant Trichophyton indotineae pose an increasing public health concern worldwide. Multidrug-resistant T. indotineae infections have been reported in China in the past few years. To understand the genetic relationship and the origin of these Chinese isolates, as well as their relationship to the global collections, we sequenced the whole genomes of 31 isolates using the Illumina platforms. Genomic epidemiology was performed on a dataset of 181 T. indotineae isolates from China and 8 other countries, representing the largest genome-wide analysis. Single nucleotide polymorphism analysis revealed that T. indotineae can be divided into four distinct phylogenetic groups (I, II, III, IV), with regional clonal transmission clusters identified in eastern China; T. indotineae was introduced into China more than once given the genetic variability. The isolates from South Asia may be the source of Chinese isolates based on epidemiological information. There were differences in the prevalence and resistance profiles among four phylogenetic groups, with Group III being predominant and exhibiting a higher terbinafine resistance rate of 88.24% and azole resistance. Also, we characterized the role of gene mutation, copy number variation, and gene expression in antifungal drug resistance. Terbinafine resistance could be mainly associated with Phe397Leu substitution in SQLE, and azole resistance might be related to increased copy number of CYP51B, as well as elevated MDR2 and MDR3 expression. Given the clinical challenges posed by T. indotineae, this emerging dermatophyte should be recognized as a global threat, necessitating urgent collaborative surveillance and management strategies.

项与特比萘芬相关的新闻（医药）

2025-11-25

·今日头条

收藏备用！8种常见皮肤病的“精准治法”，别再乱抹药膏

2025年《中国常见皮肤病诊疗指南》明确，皮肤病病因差异极大（细菌、真菌、过敏、自身免疫等），治疗必须“精准对症”。今天用大白话拆解8种高发皮肤病的“正确治法”，结合最新临床用药规范、2025年新款药物特点和科学护理理念，每个病症都标注“误区+治法+新知识点”，不管是自己用还是家人参考，收藏起来对照处理，少走冤枉路、不花冤枉钱！一、湿疹：别用强效激素，保湿是“基础治疗” 湿疹是过敏相关皮肤病，表现为皮肤发红、瘙痒、起小疹子，抓挠后可能渗液、结痂，常见于手肘、膝盖内侧、面部，儿童和成年人都容易中招。 • 常见误区：一痒就用卤米松等强效激素药膏，长期用会导致皮肤变薄、留色素沉着，甚至诱发激素依赖性皮炎。 • 正确治法： 1. 用药：轻度湿疹（仅瘙痒、少量疹子）用弱效激素药膏（如氢化可的松乳膏），每天1-2次，连续用不超过2周；中度湿疹（红、痒明显，有少量渗液）先涂氧化锌软膏收敛渗液，渗液停止后换糠酸莫米松乳膏（中弱效激素，安全性更高）；严重湿疹需在医生指导下加用口服抗组胺药（如氯雷他定）。 2. 护理：湿疹患者皮肤屏障脆弱，每天涂2次医用保湿霜（含神经酰胺、透明质酸成分）比用药更关键，2025年临床研究证实，坚持保湿可使湿疹复发率降低50%；避免用热水烫洗、肥皂搓洗，穿纯棉宽松衣服，少吃辛辣、海鲜等易过敏食物。 • 2025新知识点：婴儿湿疹多数是皮肤干燥导致，别盲目忌口，重点做好保湿；2025年推出的“湿疹专用保湿凝胶”，添加了修复因子，比普通保湿霜见效快30%，适合急性期缓解不适。二、脚气（足癣）：别用止痒药膏，抗真菌药要“用够疗程” 脚气是真菌感染引起的，分3种类型：水疱型（脚趾间、脚底起小水疱，痒得厉害）、糜烂型（脚趾间皮肤发白、脱皮，甚至渗液）、鳞屑角化型（脚跟、脚底皮肤粗糙、脱皮、开裂），传染性强。 • 常见误区：用含激素的复方止痒药膏，虽然能暂时止痒，但会抑制皮肤免疫，让真菌大量繁殖，脚气越治越重，甚至蔓延到脚背、小腿。 • 正确治法： 1. 用药：水疱型、糜烂型用联苯苄唑溶液（渗透强，适合有渗液的情况），每天1次，涂到症状消失后再用2周；鳞屑角化型用特比萘芬乳膏（膏体厚重，能软化角质），每天2次，连续用4周以上；严重脚气（全脚脱皮、开裂，或合并灰指甲）需在医生指导下口服抗真菌药（如伊曲康唑），服药期间需遵医嘱检查肝功能。 2. 护理：每天换纯棉袜子，鞋子选透气的帆布鞋或皮鞋，别穿塑料鞋、不透气的运动鞋；洗脚后擦干脚趾缝，潮湿环境容易滋生真菌；家人有脚气要分开用脚盆、拖鞋、指甲刀，避免交叉感染。 • 2025新知识点：脚气治好后别马上停药，真菌潜伏性强，多用药2-4周复发率可降低60%；2025年新款抗真菌药膏添加了“渗透增强剂”，能穿透增厚角质，对鳞屑角化型脚气疗效提升30%，且刺激性更小。三、荨麻疹（风团）：别只涂外用药，口服药才是“关键” 荨麻疹是皮肤黏膜暂时充血、水肿引起的，表现为突然起红色或苍白色风团，痒得厉害，几小时后会自行消退，但容易反复，常见诱因有过敏（食物、花粉、药物）、感染、冷热刺激、压力大等。 • 常见误区：只涂外用药膏止痒，其实荨麻疹是“全身过敏反应”，外用药只能缓解局部瘙痒，无法控制全身反复发作，还可能延误病情。 • 正确治法： 1. 用药：首选口服第二代抗组胺药（如氯雷他定、西替利嗪），每天1片，吃到风团完全不发后再逐渐减量（如隔天1片），避免突然停药；严重荨麻疹（风团遍布全身、伴呼吸困难、腹痛）需立即就医，可能要静脉用激素急救，切勿自行处理。 2. 护理：记录“过敏日记”，比如吃了某食物、接触某物品后起风团，下次避免接触；别抓挠风团，越抓越肿、越抓越痒，可冷敷（用毛巾裹冰袋）缓解瘙痒；避免喝浓茶、咖啡，别熬夜，免疫力下降会加重发作频率。 • 2025新知识点：超过6周不愈的慢性荨麻疹，别自己加药量，2025年临床常用“抗组胺药+益生菌”联合治疗，可提升治愈率20%；新款长效抗组胺药能维持24小时止痒，适合上班族和学生党。四、痤疮（痘痘）：别滥用红霉素软膏，分类型用药才“有效” 痤疮是毛囊皮脂腺炎症，表现为粉刺（黑头、白头）、丘疹（红色小疙瘩）、脓疱（顶部有小白点），常见于额头、下巴、脸颊，和油脂分泌多、毛孔堵塞、细菌感染、激素水平有关，青少年和成年人都可能出现。 • 常见误区：不管什么痘痘都涂红霉素软膏，其实红霉素是抗生素，只对脓疱型痘痘有用，对粉刺、丘疹无效，长期使用还会导致细菌耐药。 • 正确治法： 1. 用药：粉刺型（只有黑头、白头）用阿达帕林凝胶（每晚1次，能疏通毛孔），刚开始用可能脱皮、发红，需配合保湿霜建立耐受；丘疹、脓疱型（红色疙瘩、有小白点）用克林霉素凝胶+过氧化苯甲酰凝胶（白天用克林霉素，晚上用过氧化苯甲酰，杀菌消炎）；严重痤疮需在医生指导下口服抗生素（如多西环素）或异维A酸。 2. 护理：每天用温和洁面产品洗1-2次脸，别过度清洁（会刺激油脂分泌）；别用手挤痘痘，容易留痘印、痘坑；少喝含糖饮料、少吃油炸食品和高糖食物，2025年研究发现，高糖饮食会使痤疮发生率增加40%，尽量11点前入睡。 • 2025新知识点：敏感肌痤疮患者可选择新款壬二酸凝胶，温和性比阿达帕林高50%，不易脱皮；痤疮恢复期用含维生素C、烟酰胺的医用护肤品，能减少痘印形成，这是2025年皮肤科推荐的“痘印预防方案”。五、体癣（圈癣）：别用激素药膏，抗真菌药要“涂够范围” 体癣是皮肤癣菌感染引起的，表现为圆形或椭圆形红斑，边缘清晰、中间颜色变浅，伴有瘙痒，常见于躯干、四肢，多由脚气、手癣传染而来，或接触了被污染的衣物、毛巾。 • 常见误区：用激素药膏（如地塞米松乳膏），会让红斑范围扩大、瘙痒加重，甚至掩盖病情，导致体癣蔓延。 • 正确治法： 1. 用药：首选外用抗真菌药膏（如咪康唑乳膏、特比萘芬乳膏），每天2次，涂抹时要超出红斑边缘1-2厘米，确保覆盖潜在感染区域，连续用4-6周；范围大、瘙痒剧烈的需在医生指导下口服抗真菌药（如伊曲康唑）。 2. 护理：穿宽松透气的棉质衣物，避免紧身衣摩擦患处；出汗后及时洗澡，保持皮肤干燥；家里有宠物的要定期驱虫，宠物真菌可能传染给人；不与他人共用衣物、毛巾，防止交叉感染。 • 2025新知识点：体癣治疗需“同治同源”，若同时有脚气、手癣要一起治；2025年复方抗真菌药膏添加了植物止痒成分，用药后10分钟内可缓解瘙痒，提升用药依从性。六、接触性皮炎：别用偏方止痒，先“远离过敏原” 接触性皮炎是皮肤接触某些物质后引起的过敏反应，表现为接触部位发红、瘙痒、起疹子，严重时会肿胀、渗液，常见过敏原包括化妆品、洗涤剂、金属饰品、花粉、植物汁液等。 • 常见误区：用盐水、醋、牙膏等偏方止痒，这些物质会刺激皮肤，加重红肿、渗液，甚至导致皮肤破损感染。 • 正确治法： 1. 用药：轻度（仅发红、瘙痒）用炉甘石洗剂止痒，每天2-3次；中度（红肿、起疹子）用弱效激素药膏（如氢化可的松乳膏），每天1-2次，连续用不超过1周；严重（肿胀、渗液）需在医生指导下口服抗组胺药，必要时加用激素。 2. 护理：立即远离过敏原，停用新换的化妆品、摘掉金属项链；用清水清洗接触部位，去除残留过敏原；避免抓挠、热水烫洗，穿宽松透气的棉质衣物。 • 2025新知识点：不确定过敏原可去医院做“皮肤点刺试验”，明确后避免接触；2025年新款无香精、无防腐剂的医用护肤品，可降低接触性皮炎复发风险，适合敏感肌长期使用。七、银屑病（牛皮癣）：别信“根治偏方”，规范治疗是“核心” 银屑病是自身免疫性皮肤病，表现为皮肤出现红色斑块，上面覆盖银白色鳞屑，伴有瘙痒，常见于头皮、四肢伸侧，容易反复发作，和遗传、免疫力、环境因素有关。 • 常见误区：长期用强效激素药膏或偏方治疗，会导致病情反弹、加重，还可能引起皮肤萎缩、色素沉着等副作用。 • 正确治法： 1. 用药：轻度（斑块面积小、数量少）用维生素D3衍生物（如卡泊三醇软膏）+弱效激素药膏（如糠酸莫米松乳膏），交替使用，每天1次；中度至重度需在医生指导下用生物制剂（2025年临床常用司库奇尤单抗），或口服免疫抑制剂，避免自行用药。 2. 护理：保持皮肤湿润，每天涂医用保湿霜，缓解鳞屑和瘙痒；避免皮肤外伤（划伤、烫伤可能诱发新皮损）；保持心情舒畅，压力大、熬夜会加重病情；少吃辛辣刺激性食物，多吃富含维生素的蔬菜水果。 • 2025新知识点：银屑病无法根治，但通过规范治疗能有效控制症状；生物制剂的普及使中重度银屑病控制率提升至80%，且副作用比传统免疫抑制剂小，是2025年临床首选的进阶治疗方案。八、虫咬皮炎（丘疹性荨麻疹）：别用抗生素药膏，止痒+防抓挠是“重点” 虫咬皮炎是蚊虫、螨虫、跳蚤等叮咬后引起的皮肤反应，表现为孤立或小簇出现的红色丘疹，中心可能有小咬点，瘙痒剧烈，常见于四肢、躯干，儿童和户外活动多的人容易中招。 • 常见误区：担心感染而涂抗生素药膏，其实虫咬皮炎是过敏反应，无需用抗生素，只有抓挠导致皮肤破损、流脓时，才需在医生指导下使用。 • 正确治法： 1. 用药：首选炉甘石洗剂止痒，每天2-3次；瘙痒剧烈的用弱效激素药膏（如氢化可的松乳膏），每天1次，连续用不超过3天；儿童可用专用的地奈德乳膏，用量要少。 2. 护理：避免抓挠，抓破后容易感染留疤；用肥皂水清洗叮咬部位，中和蚊虫毒液；家里定期打扫卫生、晾晒被褥，防止螨虫、跳蚤滋生；户外活动时穿长袖长裤，喷驱蚊液。 • 2025新知识点：2025年新款儿童专用驱蚊液，成分是天然植物提取物，驱蚊时长可达8小时，对皮肤无刺激；叮咬后若出现大面积红肿，可冷敷后涂抹“蚊虫叮咬专用凝胶”，能快速消肿止痒。 2025皮肤病用药核心原则：安全第一，对症为先 1. 别自行诊断：皮肤症状相似但病因不同（如红斑可能是湿疹、体癣、银屑病），盲目用药只会加重病情，不确定时可去医院皮肤科就诊； 2. 激素药膏别滥用：弱效激素（如氢化可的松）可短期使用，强效激素（如卤米松）需在医生指导下使用，避免长期、大面积使用； 3. 遵医嘱疗程用药：抗真菌药、治痤疮药等需要足够疗程，症状消失后立即停药容易复发； 4. 新药需理性选：2025年新款药物虽有优势，但需结合自身症状和医生建议选择，不盲目跟风购买。最后想说：皮肤病不可怕，找对方法是关键皮肤是人体最大的器官，出现问题时别慌张，更别乱用药膏。很多人因为盲目用药，导致小毛病拖成慢性问题，既遭罪又花钱。记住，不同皮肤病的治疗核心不同——湿疹要“保湿+弱效激素”，脚气要“抗真菌+坚持疗程”，痤疮要“分类型用药+控油”。收藏这份指南，遇到对应的情况对照处理，不确定时及时就医，才能让皮肤尽快恢复健康。

2025-11-21

·简书

狗狗常见六种皮肤病症状及治疗方法

狗狗常见六种皮肤病症状及治疗方法Ⅰ. 跳蚤性皮炎（Flea Allergy Dermatitis）跳蚤性皮炎是犬类最常见的过敏性皮肤病之一，由跳蚤叮咬后唾液中的蛋白质引发免疫反应所致。临床表现为剧烈瘙痒、红斑、脱毛，尤其集中在尾根部、背部和大腿后侧。据美国兽医皮肤病学会统计，约40%的犬类过敏病例与跳蚤有关。即使环境中跳蚤数量极少，敏感个体仍可能因单次叮咬产生严重反应。诊断通常通过皮肤刮片检查或跳蚤粪便检测确认。治疗需双管齐下：一是使用经FDA或EMA批准的外用或口服驱虫剂，如含有氟雷拉纳（Fluralaner）或塞拉菌素（Selamectin）的制剂，彻底清除体表寄生虫；二是控制继发感染，必要时配合局部或系统性抗生素与糖皮质激素缓解炎症。环境治理同样关键，需同步清洁宠物寝具、地毯并使用环境杀虫喷雾，防止反复感染。Ⅱ. 真菌性皮肤病（Dermatophytosis）真菌性皮肤病，俗称“癣”，主要由犬小孢子菌（Microsporum canis）引起，具有高度传染性，可传播至人类及其他动物。典型症状包括圆形脱毛斑、鳞屑、结痂，边缘隆起呈环状，常见于面部、耳尖和四肢。伍德氏灯检查在部分病例中可使病灶发出苹果绿色荧光，但确诊需依赖真菌培养，通常耗时7–14天。据《Veterinary Dermatology》期刊数据，该病在幼犬和免疫力低下犬中发病率更高。治疗首选口服抗真菌药物，如伊曲康唑（Itraconazole）或特比萘芬（Terbinafine），疗程一般为4–8周。同时建议配合每周两次的抗真菌药浴（如含氯己定与咪康唑的洗剂），以减少环境传播风险。患病犬应隔离饲养，所有接触物品需高温消毒，避免交叉感染。Ⅲ. 细菌性毛囊炎（Bacterial Folliculitis）细菌性毛囊炎多由金黄色葡萄球菌（Staphylococcus pseudintermedius）过度增殖引发，常继发于其他皮肤屏障损伤因素，如过敏、寄生虫或内分泌疾病。典型表现为红色丘疹、脓疱、结痂及广泛性脱毛，触诊有疼痛感。细胞学检查可在显微镜下观察到大量革兰氏阳性球菌和中性粒细胞，是确诊的关键手段。治疗以抗生素为主，根据药敏试验结果选择敏感药物，常用头孢氨苄（Cephalexin）或克林霉素（Clindamycin），疗程不少于3–4周，以防复发。局部护理推荐使用抗菌香波（如含苯氧乙醇或氯己定成分），每周2–3次，有助于减少细菌负荷。长期反复发作者需排查潜在病因，如甲状腺功能减退或食物过敏。Ⅳ. 特应性皮炎（Atopic Dermatitis）特应性皮炎是一种遗传性免疫介导的慢性炎症性皮肤病，影响全球约10%–15%的犬只。主要诱因为空气中的过敏原，如尘螨、花粉、霉菌孢子等。临床表现为季节性或常年性瘙痒，常见于面部、爪间、腋下和腹部。皮肤常伴色素沉着、油脂分泌增多及继发感染。诊断依赖排除法，结合血清特异性IgE检测或皮内过敏原测试。国际兽医皮肤病学会（ISCAID）推荐阶梯式管理方案：轻度病例可使用局部保湿剂与抗炎喷雾；中重度需引入免疫调节药物，如环孢素A（每日5 mg/kg）或靶向生物制剂洛度沙胺（Lokivetmab），后者在临床试验中显示80%以上患犬瘙痒评分下降超50%。长期管理强调环境控制，如使用HEPA空气净化器、定期清洗寝具，减少过敏原暴露。Ⅴ. 酵母菌感染（Malassezia Dermatitis）马拉色菌是一种条件致病性酵母，正常情况下存在于犬类皮肤表面，但在皮脂分泌旺盛或免疫失衡时可过度繁殖，引发炎症。典型症状为油腻性皮屑、褐色渗出物、强烈异味，常见于耳道、唇周、腋窝及趾间。细胞学检查可见典型的花生形酵母细胞。短头颅品种如巴哥犬、西施犬更易患病。治疗以抗真菌药物为核心，局部使用含酮康唑或奥昔康唑的洗剂，每周2–3次，持续4–6周。严重病例需口服伊曲康唑，剂量为5–10 mg/kg/日，疗程视病情而定。辅助治疗包括调节皮脂分泌的Omega-3脂肪酸补充，以及控制基础病因，如过敏或内分泌紊乱。Ⅵ. 自体免疫性皮肤病（Autoimmune Skin Diseases）自体免疫性皮肤病较为罕见但病情严重，代表疾病为落叶型天疱疮（Pemphigus foliaceus），占犬类自免性皮肤病的70%以上。其特征为免疫系统错误攻击表皮细胞间连接蛋白，导致水疱、脓疱迅速破溃形成糜烂与厚痂，常见于鼻梁、眼周及耳廓。组织病理学活检是确诊金标准，可见表皮内嗜酸性粒细胞浸润与棘层松解。治疗依赖免疫抑制疗法，首选泼尼松龙（Prednisolone），初始剂量为2–4 mg/kg/日，逐步递减至最低维持量。部分病例需联合硫唑嘌呤或环孢素以减少激素副作用。治疗期间需密切监测血常规与肝酶水平，预防继发感染。早期干预可显著改善预后，延长无病生存期。

2025-11-11

·mobergpharma.com

Moberg Pharma interim report January - September 2025

NINE-MONTH PERIOD (JAN-SEP 2025) Net revenue SEK 11.5 million (8.8) EBITDA SEK -18.7 million (-15.7) Operating profit (EBIT) SEK -19.9 million (-16.7) Profit for the period SEK -14.5 million (-11.8) Diluted earnings per share SEK -0.31 (-0.34) Cash and cash equivalents amounted to SEK 236.2 million (309.0) THIRD QUARTER (JUL-SEP 2025) Net revenue SEK 4.0 million (3.9) EBITDA SEK -5.6 million (-3.0) Operating profit (EBIT) SEK -6.0 million (-3.3) Profit for the period SEK -4.3 million (-1.3) Diluted earnings per share SEK -0.09 (-0.03) Cash and cash equivalents amounted to SEK 236.2 million (309.0) SIGNIFICANT EVENTS DURING THE THIRD QUARTER Sales data remain strong with 47% market share in Sweden and 37% in Norway for the third quarter Extraordinary General Meeting on September 29 resolved to expand the Board of Directors with two members, Fredrik Blom and Mona Zhang, and to revoke the authorization to issue shares, as the company is well-capitalized and does not foresee a need to utilize the authorization. SIGNIFICANT EVENTS AFTER THE QUARTER Moberg Pharma and Karo Healthcare enter exclusive license agreement for MOB-015/Terclara® in Europe. The agreement comprises 19 European markets, enabling a coordinated launch across all key EU markets under the leading global antifungal brand Lamisil®. Norway: Terclara® launch nominated for “Launch of the Year” by the pharmacy chains Apotek 1 and Alliance Healthcare CEO COMMENTS Following the successes in the Nordic region, Moberg Pharma is now taking the next step into Europe. The new license agreement with Karo Healthcare provides broad market coverage, strong distribution, and the launch of MOB-015/Terclara® under the globally leading antifungal brand Lamisil®. The agreement represents an important milestone on the path toward European market leadership. The collaboration with Karo Healthcare provides us with a clear path to market in all countries where approvals have already been granted, enabling a coordinated launch across 19 countries, including all major EU markets and the UK, representing a population of approximately 500 million people. Karo Healthcare will be responsible for and finance marketing, distribution, and sales, while we will receive recurring royalty revenues and compensation for delivered products. This gives us a stable and scalable revenue base without the need to establish local sales organizations in each market. At the same time, the company remains committed to playing an active commercial role in other territories, particularly in the U.S., as part of our long-term value creation strategy. Launching MOB-015/Terclara® under the leading global antifungal brand Lamisil® provides exceptional conditions for taking a leading position in the major European markets. Lamisil® is the original brand for terbinafine tablets, long established as the gold standard oral treatment for nail fungus. To now be able to introduce our topical terbinafine product under this strong brand is an important success for Moberg Pharma. Karo Healthcare is a leading European consumer healthcare company with ambitious growth plans, a strong owner in KKR, and established distribution across all major pharmacy chains in Europe. Through this collaboration, MOB-015/Terclara® gains broad market coverage and effective distribution right from the outset, which would take us significant time to build independently. The next step involves a regulatory process in which the use of the Lamisil® brand for MOB-015/Terclara® must be approved by the relevant national health authorities. Our ambition is to launch as soon as possible thereafter. Together with Karo Healthcare, Moberg Pharma is now taking a decisive step toward establishing MOB-015/Terclara® as the new market leader in nail fungus treatment across Europe. At home, Terclara® continues to dominate the Swedish market. 1 ½ years into the Swedish launch we are seeing market shares continue to increase despite that we have been market leader from day 1. For us, this demonstrates that Terclara not only was an initial launch success but that patients, pharmacy staff and physicians truly appreciate the product. During the quarter, Terclara® achieved a 47% value share and 40% unit share of pharmacy sales to end-consumers[1], an improvement by 13 and 12 percentage points, respectively, compared with the previous year. In Norway, consumer sales data is not reported, but based on pharmacy purchasing data the market share was 37% in value and 35% in units during the quarter[2]. The nomination of Terclara® as “Launch of the Year” in Norway by Apotek 1 and Alliance Healthcare is a further recognition of the strong work carried out in collaboration with our partner Allderma. Norway is clear proof that the success is scalable, our launch strategy works, and that demand for effective topical treatments is strong in several markets. We are now entering a new phase in Moberg Pharma's journey, from Nordic success to European growth. The partnership with Karo Healthcare and the use of the Lamisil® brand provide a unique platform for expansion, while our achievements in Sweden and Norway confirm that our model works. With strong partners, dedicated employees, and a clear vision, I am confident that we are facing a very exciting future. Anna Ljung, CEO Moberg Pharma. [1] Source: IQVIA MIDAS, Pharmacy Sell-Out data, Jul-Sep 2025 [2] Source: IQVIA MIDAS, Pharmacy Sell-In data, Jul-Sep 2025 ABOUT THIS INFORMATION This information is information that Moberg Pharma is Obliged to make public persuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, at 8.00 a.m. CET on November 11th, 2025. FOR ADDITIONAL INFORMATION Anna Ljung, CEO, Phone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se Mark Beveridge, VP Finance, Phone: +46 76 805 82 88, e-mail: mark.beveridge@mobergpharma.se

引进/卖出上市批准财报

100 项与特比萘芬相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02375	特比萘芬	D01AE15 D01BA02	DB00857

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
股癣	美国	Karo Healthcare AB	2006-07-24
糠疹	美国	Karo Healthcare AB	1998-04-29
癣	美国	Karo Healthcare AB	1998-04-29
体癣	美国	Karo Healthcare AB	1998-04-29
足癣	美国	Karo Healthcare AB	1998-04-29
花斑癣	美国	Karo Healthcare AB	1998-04-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
甲癣	临床3期	美国	Novartis Pharmaceuticals Canada, Inc.	2006-12-01
甲癣	临床3期	加拿大	Novartis Pharmaceuticals Canada, Inc.	2006-12-01
甲癣	临床3期	法国	Novartis Pharmaceuticals Canada, Inc.	2006-12-01
甲癣	临床3期	德国	Novartis Pharmaceuticals Canada, Inc.	2006-12-01
甲癣	临床3期	冰岛	Novartis Pharmaceuticals Canada, Inc.	2006-12-01
真菌病	临床1期	-	GSK Plc	2011-02-24
肝细胞癌	临床前	中国	中山大学肿瘤防治中心	2025-09-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02798380 (CTgov)	临床2期	甲癣	30	HTS-519 Insert	淵鑰範夢鹽餘製顧襯壓(夢獵願簾顧構鬱顧觸鬱) = 壓膚鏇鬱憲獵廠觸繭構襯襯網醖鹽顧鹹積鑰鬱 (夢觸範艱積蓋積膚築顧, 願積範構鏇遞窪觸糧夢 ~ 製襯鏇積鹹廠夢範窪繭) 更多	-	2019-09-24
NCT01433107 (CTgov)	临床3期	足癣	290	Terbinafine (Terbinafine)	選鏇齋淵壓顧構繭遞糧 = 製鏇糧獵築糧夢願壓壓製淵衊鬱窪簾窪餘鏇憲 (憲選齋壓窪襯鏇襯衊糧, 鹽憲憲積構製淵蓋夢糧 ~ 齋獵選餘餘衊繭鏇鹹淵) 更多	-	2013-12-27
				Terbinafine Placebo (Placebo)	選鏇齋淵壓顧構繭遞糧 = 鏇壓選淵積壓廠艱築願製淵衊鬱窪簾窪餘鏇憲 (憲選齋壓窪襯鏇襯衊糧, 鬱糧鑰鹽鹹夢廠顧鹽鏇 ~ 憲鹽選鏇襯積夢鑰製願) 更多
NCT00443898 (CTgov)	临床3期	甲癣	518	Terbinafine (Terbinafine 24 w)	夢獵鬱鏇衊簾構鹹繭獵 = 蓋網醖獵製選淵憲窪廠繭網廠醖糧願窪艱網築 (遞築選選醖淵壓築選餘, 蓋鏇壓壓淵醖襯製鬱餘 ~ 鏇願餘築淵壓艱鏇膚範) 更多	-	2011-04-20
				placebo (Vehicle 24 w)	夢獵鬱鏇衊簾構鹹繭獵 = 積醖選鏇鬱膚獵鹽蓋齋繭網廠醖糧願窪艱網築 (遞築選選醖淵壓築選餘, 鹽齋繭積積餘鹹鹽蓋衊 ~ 鹹憲鹹鹽廠願鏇衊壓簾) 更多
NCT00443820 (CTgov)	临床3期	甲癣	526	Terbinafine (Terbinafine 24 Weeks)	簾製膚願築構艱壓鏇築 = 衊窪遞網膚鬱簾願淵鹹膚顧積襯蓋鏇廠壓範築 (憲鑰構遞膚廠鹹糧製鑰, 艱艱廠願廠憲醖製顧積 ~ 窪構鑰餘簾鹽鏇願簾觸) 更多	-	2011-04-19
				placebo (Vehicle 24 Weeks)	簾製膚願築構艱壓鏇築 = 鬱獵淵齋網網願網獵廠膚顧積襯蓋鏇廠壓範築 (憲鑰構遞膚廠鹹糧製鑰, 遞範簾醖顧範壓壓廠獵 ~ 構鏇鏇鹹襯積積糧齋網) 更多